Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials

What is it about?

We investigated the heart and kidney benefits of a class of drugs called GLP-1RAs in type 2 diabetes (T2D) using adding new data from two recent trials. Our findings show that GLP-1RAs given either by mouth or by injection reduce major heart events, death and heart failure and kidney problems by the same amount, supporting the use of either in people living with T2D.

Featured Image